https://www.selleckchem.com/products/c381.html
NF-κB inhibitor, BAY 11-7082, suppressed decitabine-induced CD4 T cell proliferation and IFN-γ production. In terms of mechanism, low-dose decitabine augmented the expression of E3 ligase β-TrCP, promoted the ubiquitination and degradation of IκBα and resulted in NF-κB activation. Notably, we observed that low-dose decitabine treatment induced NF-κB activation in CD4 T cells from patients with a response to decitabine-primed chemotherapy rather than those without a response. These data suggest that low-dose decitabine potentiates CD4 T cel
Like
Comment
Share
